Biclonal gammopathy in chronic lymphocytic leukemia

Case report and review of the literature

Nafila Al-Riyami, Khalil Al-Farsi, Khalfan Al-Amrani, Sameera Al-Harrasi, Mohammed Al-Huneini, Salam Al-Kindi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Monoclonal gammopathies are frequently seen in B-cell malignancies. Monoclonal proteins are seen in a significant proportion of patients with chronic lymphocytic leukemia (CLL), which is a clonal disorder of mature B cells. The use of more sensitive laboratory methods has enabled the detection of monoclonal proteins or light chains in the serum and/or urine in the majority of these patients. The presence of some of these monoclonal proteins may explain the different autoimmune phenomena that are associated with this disease. Some reports indicate that the finding of monoclonal proteins has a negative impact on patients’ survival. The presence of two different monoclonal proteins (i.e. biclonal gammopathy) is on the other hand rare. Most of the reported cases in the literature are of patients with plasma cell disorders. In this report, we describe a rare occurrence of biclonal gammopathy in a patient with CLL. Serum protein electrophoresis and immunofixation, which were negative at the time of initial diagnosis, showed biclonal immunoglobin A (IgA) kappa and IgA lambda during the course of the disease. The patient’s disease showed steady progression, despite multiple treatments. Although this could just be the result of using more sensitive laboratory techniques, biclonal gammopathy in this patient likely reflects the evolution of another clone, which would explain the encountered resistance to therapy. Because of paucity of reports, the impact of biclonal gammopathies in such patients is not known and an effort to collectively report the presentation and outcome of these patients is needed to further understand the pathophysiology and clinical significance of such a finding.

Original languageEnglish
Pages (from-to)217-218
Number of pages2
JournalOman Medical Journal
Volume30
Issue number3
DOIs
Publication statusPublished - 2015

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Proteins
B-Lymphocytes
Paraproteinemias
Plasma Cells
Electrophoresis
Blood Proteins
Clone Cells
Urine
Light
Survival
Therapeutics
Serum

Keywords

  • B-Cell
  • Chronic Lymphocytic
  • Leukemia
  • Leukemia
  • Paraproteinemias

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Biclonal gammopathy in chronic lymphocytic leukemia : Case report and review of the literature. / Al-Riyami, Nafila; Al-Farsi, Khalil; Al-Amrani, Khalfan; Al-Harrasi, Sameera; Al-Huneini, Mohammed; Al-Kindi, Salam.

In: Oman Medical Journal, Vol. 30, No. 3, 2015, p. 217-218.

Research output: Contribution to journalArticle

@article{7aa3253164a44ff68b4414eae955ae40,
title = "Biclonal gammopathy in chronic lymphocytic leukemia: Case report and review of the literature",
abstract = "Monoclonal gammopathies are frequently seen in B-cell malignancies. Monoclonal proteins are seen in a significant proportion of patients with chronic lymphocytic leukemia (CLL), which is a clonal disorder of mature B cells. The use of more sensitive laboratory methods has enabled the detection of monoclonal proteins or light chains in the serum and/or urine in the majority of these patients. The presence of some of these monoclonal proteins may explain the different autoimmune phenomena that are associated with this disease. Some reports indicate that the finding of monoclonal proteins has a negative impact on patients’ survival. The presence of two different monoclonal proteins (i.e. biclonal gammopathy) is on the other hand rare. Most of the reported cases in the literature are of patients with plasma cell disorders. In this report, we describe a rare occurrence of biclonal gammopathy in a patient with CLL. Serum protein electrophoresis and immunofixation, which were negative at the time of initial diagnosis, showed biclonal immunoglobin A (IgA) kappa and IgA lambda during the course of the disease. The patient’s disease showed steady progression, despite multiple treatments. Although this could just be the result of using more sensitive laboratory techniques, biclonal gammopathy in this patient likely reflects the evolution of another clone, which would explain the encountered resistance to therapy. Because of paucity of reports, the impact of biclonal gammopathies in such patients is not known and an effort to collectively report the presentation and outcome of these patients is needed to further understand the pathophysiology and clinical significance of such a finding.",
keywords = "B-Cell, Chronic Lymphocytic, Leukemia, Leukemia, Paraproteinemias",
author = "Nafila Al-Riyami and Khalil Al-Farsi and Khalfan Al-Amrani and Sameera Al-Harrasi and Mohammed Al-Huneini and Salam Al-Kindi",
year = "2015",
doi = "10.5001/omj.2015.45",
language = "English",
volume = "30",
pages = "217--218",
journal = "Oman Medical Journal",
issn = "1999-768X",
publisher = "Oman Medical Specialty Board",
number = "3",

}

TY - JOUR

T1 - Biclonal gammopathy in chronic lymphocytic leukemia

T2 - Case report and review of the literature

AU - Al-Riyami, Nafila

AU - Al-Farsi, Khalil

AU - Al-Amrani, Khalfan

AU - Al-Harrasi, Sameera

AU - Al-Huneini, Mohammed

AU - Al-Kindi, Salam

PY - 2015

Y1 - 2015

N2 - Monoclonal gammopathies are frequently seen in B-cell malignancies. Monoclonal proteins are seen in a significant proportion of patients with chronic lymphocytic leukemia (CLL), which is a clonal disorder of mature B cells. The use of more sensitive laboratory methods has enabled the detection of monoclonal proteins or light chains in the serum and/or urine in the majority of these patients. The presence of some of these monoclonal proteins may explain the different autoimmune phenomena that are associated with this disease. Some reports indicate that the finding of monoclonal proteins has a negative impact on patients’ survival. The presence of two different monoclonal proteins (i.e. biclonal gammopathy) is on the other hand rare. Most of the reported cases in the literature are of patients with plasma cell disorders. In this report, we describe a rare occurrence of biclonal gammopathy in a patient with CLL. Serum protein electrophoresis and immunofixation, which were negative at the time of initial diagnosis, showed biclonal immunoglobin A (IgA) kappa and IgA lambda during the course of the disease. The patient’s disease showed steady progression, despite multiple treatments. Although this could just be the result of using more sensitive laboratory techniques, biclonal gammopathy in this patient likely reflects the evolution of another clone, which would explain the encountered resistance to therapy. Because of paucity of reports, the impact of biclonal gammopathies in such patients is not known and an effort to collectively report the presentation and outcome of these patients is needed to further understand the pathophysiology and clinical significance of such a finding.

AB - Monoclonal gammopathies are frequently seen in B-cell malignancies. Monoclonal proteins are seen in a significant proportion of patients with chronic lymphocytic leukemia (CLL), which is a clonal disorder of mature B cells. The use of more sensitive laboratory methods has enabled the detection of monoclonal proteins or light chains in the serum and/or urine in the majority of these patients. The presence of some of these monoclonal proteins may explain the different autoimmune phenomena that are associated with this disease. Some reports indicate that the finding of monoclonal proteins has a negative impact on patients’ survival. The presence of two different monoclonal proteins (i.e. biclonal gammopathy) is on the other hand rare. Most of the reported cases in the literature are of patients with plasma cell disorders. In this report, we describe a rare occurrence of biclonal gammopathy in a patient with CLL. Serum protein electrophoresis and immunofixation, which were negative at the time of initial diagnosis, showed biclonal immunoglobin A (IgA) kappa and IgA lambda during the course of the disease. The patient’s disease showed steady progression, despite multiple treatments. Although this could just be the result of using more sensitive laboratory techniques, biclonal gammopathy in this patient likely reflects the evolution of another clone, which would explain the encountered resistance to therapy. Because of paucity of reports, the impact of biclonal gammopathies in such patients is not known and an effort to collectively report the presentation and outcome of these patients is needed to further understand the pathophysiology and clinical significance of such a finding.

KW - B-Cell

KW - Chronic Lymphocytic

KW - Leukemia

KW - Leukemia

KW - Paraproteinemias

UR - http://www.scopus.com/inward/record.url?scp=84935028409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84935028409&partnerID=8YFLogxK

U2 - 10.5001/omj.2015.45

DO - 10.5001/omj.2015.45

M3 - Article

VL - 30

SP - 217

EP - 218

JO - Oman Medical Journal

JF - Oman Medical Journal

SN - 1999-768X

IS - 3

ER -